Genelux (GNLX) Other Non-Current Assets (2022 - 2026)

Genelux (GNLX) posted quarterly Other Non-Current Assets of $144000.0 for Q1 2026, little changed quarter-over-quarter from $144000.0 in Q4 2025.

Genelux (GNLX) Other Non-Current Assets (2022 - 2026) Analysis & Trends

Genelux's Other Non-Current Assets history runs 5 years deep, the most recent figure standing at $144000.0 for Q1 2026.

In Q1 2026, Other Non-Current Assets changed N/A year-over-year to $144000.0; the TTM figure through Mar 2026 stood at $144000.0 (changed N/A YoY), while the FY2025 annual figure was $144000.0, up 56.52% from the prior year.
Other Non-Current Assets for Q1 2026 stood at $144000.0, roughly flat from $144000.0 in the prior quarter.
The five-year high for Other Non-Current Assets was $144000.0 in Q4 2025, with the low at $73000.0 in Q2 2025.
The 5-year median for Other Non-Current Assets is $92000.0 (2022), against an average of $102545.5.
Peak annual rise in Other Non-Current Assets reached 56.52% in 2025, while the deepest fall reached 20.65% in 2025.
Genelux's Other Non-Current Assets stood at $92000.0 in 2022, then changed by 0.0% to $92000.0 in 2023, then changed by 0.0% to $92000.0 in 2024, then surged by 56.52% to $144000.0 in 2025, then changed by 0.0% to $144000.0 in 2026.
Business Quant data shows GNLX's Other Non-Current Assets at $144000.0 in Q1 2026, $144000.0 in Q4 2025, and $123000.0 in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Other Non-Current Assets (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	1.25 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	2.31 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	124.00 Mn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	618.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	109.58 Mn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	65.13 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	104.44 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	62.96 Mn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	202.31 Mn
10	Genelux	120.53 Mn	120.53 Mn	-	144,000.00

Download Data